BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bliss-Moreau M, Coarfa C, Gunaratne PH, Guitart J, Krett NL, Rosen ST. Identification of p38β as a therapeutic target for the treatment of Sézary syndrome. J Invest Dermatol 2015;135:599-608. [PMID: 25148579 DOI: 10.1038/jid.2014.367] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 García-Hernández L, García-Ortega MB, Ruiz-Alcalá G, Carrillo E, Marchal JA, García MÁ. The p38 MAPK Components and Modulators as Biomarkers and Molecular Targets in Cancer. Int J Mol Sci 2021;23:370. [PMID: 35008796 DOI: 10.3390/ijms23010370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Patil K, Kuttikrishnan S, Khan AQ, Ahmad F, Alam M, Buddenkotte J, Ahmad A, Steinhoff M, Uddin S. Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways. Semin Cancer Biol 2021:S1044-579X(21)00296-0. [PMID: 34906723 DOI: 10.1016/j.semcancer.2021.12.003] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Zhang XH, Hsiang J, Rosen ST. Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma. J Clin Haematol 2021;2:48-61. [PMID: 34223559 DOI: 10.33696/haematology.2.028] [Reference Citation Analysis]
4 Roche O, Fernández-Aroca DM, Arconada-Luque E, García-Flores N, Mellor LF, Ruiz-Hidalgo MJ, Sánchez-Prieto R. p38β and Cancer: The Beginning of the Road. Int J Mol Sci 2020;21:E7524. [PMID: 33053909 DOI: 10.3390/ijms21207524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Zhang XH, Nam S, Wu J, Chen CH, Liu X, Li H, McKeithan T, Gong Q, Chan WC, Yin HH, Yuan YC, Pillai R, Querfeld C, Horne D, Chen Y, Rosen ST. Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma. J Invest Dermatol 2018;138:2377-87. [PMID: 29758280 DOI: 10.1016/j.jid.2018.04.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
6 Zou X, Blank M. Targeting p38 MAP kinase signaling in cancer through post-translational modifications. Cancer Lett. 2017;384:19-26. [PMID: 27725227 DOI: 10.1016/j.canlet.2016.10.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
7 Fredholm S, Litvinov IV, Mongan NP, Schiele S, Willerslev-olsen A, Petersen D, Krejsgaard T, Sibbesen N, Nastasi C, Bonefeld CM, Persson JL, Straten PT, Andersen M, Koralov SB, Wasik MM, Geisler C, Sasseville D, Woetmann A, Ødum N. The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology 2016;136:866-9. [DOI: 10.1016/j.jid.2015.12.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
8 Nicolay JP, Felcht M, Schledzewski K, Goerdt S, Géraud C. Sézary syndrome: old enigmas, new targets. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2016;14:256-64. [DOI: 10.1111/ddg.12900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
9 Thomas AL, Coarfa C, Qian J, Wilkerson JJ, Rajapakshe K, Krett NL, Gunaratne PH, Rosen ST. Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma. Nucl Recept Signal 2015;13:e006. [PMID: 26715915 DOI: 10.1621/nrs.13006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nichols A, Kirsner RS. JID VisualDx Quiz: February 2015. J Invest Dermatol 2015;135:1-2. [PMID: 25573049 DOI: 10.1038/jid.2014.496] [Reference Citation Analysis]